Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Common Equity (2020 - 2023)

Candel Therapeutics' Common Equity history spans 4 years, with the latest figure at $23.0 million for Q3 2023.

  • For Q3 2023, Common Equity fell 55.83% year-over-year to $23.0 million; the TTM value through Sep 2023 reached $23.0 million, down 55.83%, while the annual FY2022 figure was $47.7 million, 25.61% down from the prior year.
  • Common Equity for Q3 2023 was $23.0 million at Candel Therapeutics, down from $30.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $64.1 million in Q4 2021 and bottomed at -$43.2 million in Q2 2021.
  • The 4-year median for Common Equity is $35.2 million (2023), against an average of $23.1 million.
  • The largest YoY upside for Common Equity was 525.13% in 2021 against a maximum downside of 249.85% in 2021.
  • A 4-year view of Common Equity shows it stood at -$23.6 million in 2020, then surged by 372.21% to $64.1 million in 2021, then decreased by 25.61% to $47.7 million in 2022, then plummeted by 51.75% to $23.0 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Common Equity are $23.0 million (Q3 2023), $30.8 million (Q2 2023), and $39.7 million (Q1 2023).